News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
Publication
Dermatology Times
More
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
    • Biologic Treatments for Moderate to Severe Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
    • Emerging Therapies Plaque Psoriasis
    • Treatments for Plaque Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Skin Cancer (Nonmelanoma)
  • Vitiligo
  • Wound Care
Spotlight -
NP and PA
Advertisement

Amit Pandya, MD

Advertisement

Articles by Amit Pandya, MD

Advancing Medical Treatments for Vitiligo With Amit Pandya, MD, FAAD

ByAmit Pandya, MD,Kaitlyn Bader, Senior Editor
May 15th 2023

Pandya gives an in-depth overview of his vitiligo treatment pearls from the 2023 Pigmentary Disorders Exchange Symposium.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Dermatology Times

    1

    Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

    2

    Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC

    3

    Phase 2 Nemolizumab Trial Opens for CPUO

    4

    First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA

    5

    Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1

    • About
    • Advertise
    • Contact Us
    • Job Board
    • Do Not Sell My Information
    • Terms and Conditions
    • Privacy Policy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us